Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2011-03-29
2011-03-29
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S009100, C514S002600, C514S012200
Reexamination Certificate
active
07914771
ABSTRACT:
The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
REFERENCES:
patent: 4732973 (1988-03-01), Barr et al.
patent: 4752576 (1988-06-01), Brake et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4870008 (1989-09-01), Brake
patent: 5008242 (1991-04-01), Lezdey et al.
patent: 5093316 (1992-03-01), Lezdey et al.
patent: 5114953 (1992-05-01), Galardy et al.
patent: 5134119 (1992-07-01), Lezdey et al.
patent: 5166134 (1992-11-01), Lezdey et al.
patent: 5217951 (1993-06-01), Lezdey et al.
patent: 5256657 (1993-10-01), Singh et al.
patent: 5290762 (1994-03-01), Lezdey et al.
patent: 5594106 (1997-01-01), Black et al.
patent: 5618786 (1997-04-01), Roosdorp et al.
patent: 5696147 (1997-12-01), Galardy
patent: 5773438 (1998-06-01), Levy et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5892112 (1999-04-01), Levy et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 5993783 (1999-11-01), Eljamal et al.
patent: 6068994 (2000-05-01), Barr et al.
patent: 6124257 (2000-09-01), Lezdey et al.
patent: 6133304 (2000-10-01), Peterson, Jr. et al.
patent: RE37053 (2001-02-01), Hanes et al.
patent: 6469040 (2002-10-01), Seibert et al.
patent: 6489308 (2002-12-01), Shapiro et al.
patent: 6544497 (2003-04-01), Zhu et al.
patent: 6693096 (2004-02-01), Fritz et al.
patent: 6740655 (2004-05-01), Magee et al.
patent: 7247704 (2007-07-01), Barr et al.
patent: 2001/0006939 (2001-07-01), Niven et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2003/0068280 (2003-04-01), Bannister et al.
patent: 2003/0073217 (2003-04-01), Barr et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0211548 (2003-11-01), Packard et al.
patent: 2005/0201951 (2005-09-01), Barr et al.
patent: 2008/0312136 (2008-12-01), Durrani et al.
patent: 0 648 838 (1995-04-01), None
patent: 1 226 119 (2002-07-01), None
patent: 1 226 136 (2002-07-01), None
patent: 1 047 450 (2002-10-01), None
patent: WO 92/09282 (1992-06-01), None
patent: WO 92/09556 (1992-06-01), None
patent: WO 92/09563 (1992-06-01), None
patent: WO 93/13741 (1993-07-01), None
patent: WO 94/02446 (1994-02-01), None
patent: WO 94/21625 (1994-09-01), None
patent: WO 94/22309 (1994-10-01), None
patent: WO 95/09841 (1995-04-01), None
patent: WO 95/19965 (1995-07-01), None
patent: WO 96/16027 (1996-05-01), None
patent: WO 96/32152 (1996-10-01), None
patent: WO 97/42168 (1997-11-01), None
patent: WO 98/07742 (1998-02-01), None
patent: WO 98/14424 (1998-04-01), None
patent: WO 98/43946 (1998-10-01), None
patent: WO 98/47863 (1998-10-01), None
patent: WO 99/32150 (1999-07-01), None
patent: WO 99/44989 (1999-09-01), None
patent: WO 00/34237 (2000-06-01), None
patent: WO 02/50287 (2002-06-01), None
patent: WO 02/053138 (2002-07-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 03/068188 (2003-08-01), None
patent: WO 03/075959 (2003-09-01), None
patent: WO 2004/103364 (2004-12-01), None
patent: WO 2005/003150 (2005-01-01), None
Barnes, Peter J., “Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease”, Am. J. Respir. Crit. Care Med. vol. 160, pp. S72-S79, 1999.
Travis, James et al., “Isolation and Properties of Recombinant DNA Produced Variants of Human Proteinase Inhibitor”, The Journal of Biological Chemistry, vol. 260, No. 7, Issue of Apr. 10, pp. 4384-4389, 1985.
Roche, N. et al., “Current issues in the management of chronic obstructive pulmonary diseases”, Respirology, vol. 2, pp. 215-229, 1997.
He, J.Q. et al., “Pharnacogenomics of COPD”, Current Pharmacogenomics, pp. 229-243, 2003.
Churg et al., “Proteases and Emphysema”, Current Opinion in Pulmonary Medicine 11:153-159 (2005).
Huang et al., “Expression and Purification of Functional Human al-Antitrypsin from Cultured Plant Cells”, Biotechnol Prog. 17, 126-33 (2001).
Rabe, “Outcome Measures in COPD”, Primary Care Respiratory Journal, 13:177-178 (2004).
Rosenerg et al., “Synthesis in Yeast of a Functional Oxidation-Resistant Mutant of Human al-Antitrypsin”, Nature vol. 312, pp. 77-80, (1984).
Shapiro, “Envolving Concepts in the Pathogenesis of Chronic Obstructive Pulmonary Disease”, Clinics in Chest Medicine, vol. 21, No. 4, pp. 621-632, (2000).
Travis et al., “Isolation and Properties of Recombinant DNA Produced Variants of Human al-Proteinase Inhibitor”, Journal of Biological Chemistry, vol. 260, No. 7, pp. 4384-4389, (1985).
Terashima et al., “Production of Functional Human al-Antitrypsin by Plant Cell Culture”, Appl. Microbiol Biotechnol, 52:516-23 (1999).
Beatty, K., et al., “Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin,”J. Biol. Chem.—255(9):3931-3934 (1980).
Carrell, R.W., et al., “Structure and variation of human alpha 1-antitrypsin”,Nature—298:329-334 (1982).
Hercz, A., “Proteolytic cleavages in alpha-one antitrypsin and microheterogeneity,”Biochem. Biophys. Res. Comm.—128(1): 199-203 (1985).
Schasteen, C.S., et al., “Synthetic peptide inhibitors of complement serine proteases—III. Significant increase in inhibitor potency provides further support for the functional equivalence hypothesis,”Mol. Immunol. 28(1/2):17-26 (1991).
Stolk, et al., “Progression parameters for emphysema: A clinical investigation,”Respiratory Medicine.—(101) 1924-1930 (2007).
Stockley, et al., “Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis”,European Respiratory Society—(Abstract) Oct. 7, 2008.
Pemberton, Philip A., et al., “Inhaled Recombinant Alpha 1-Antitrypsin Ameliorates Cigarette Smoke-Induced Emphysema in the Mouse”, COPD:Journal of Chronic Obstructive Pulmonary Disease, 3:101-108, 2006.
Barnes, P. J., “Chronic Obstructive Pulmonary Disease,” The New England Journal of Medicine, 343(4): 269-280, 2000.
Barnes, P. J., “Mechanisms in COPD; Differences From Asthma,” Chest, 117(2): I0S-14S, 2000.
Barnes, P.J., “Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine, 160(5): S72-S79, 1999.
Bingle L. et al., “Susceptibility of Lung Epithelium to Neutrophil Elastase: Protection by Native Inhibitors,” Mediators of Inflammation, 6:345-354, 1997.
Bingle, et al., “Secretory leukoprotease inhibitor: Partnering α1-proteinase inhibitor to combat pulmonary inflammation,” 51: 1273-1274, 1996.
Bode, W., et al., “Proteinase-Protein Inhibitor Interactions,” Fibrinolysis, 8(1): 161-171, 1994.
Levels on the Respiratory Epithelial Surface by Aerosolization of Recombinant Secretory Leukoprotease Inhibitor, The J. of Clin. Inves., 90: 1296-1301, 1992.
Okayama, H., et al., “Characterization of the Coding Sequence of the Normal M4 α1-Antitrypsin Gene,” Biochem. Biophys. Res. Commun., 162(3): 1560-1570, 1989.
Okayama, H., et al., Am. J. Hum. Genet., 48(6): 1154-1158, 1991.
Patterson, S.D., “Mammalian α1-Antitrypsins: Comparative Biochemistry and Genetics of the Major Plasma Serpin,” Comp Biochem. Physiol., 100B(3):439-454, 1991.
Potempa, J., et al., “The Serpin Superfamily of Proteinase Inhibitors: Structure, Function, and Regulation,” The J. of Biol. Chem., 269(23): 15957-15960,1994.
Prouty, R., Office Action in U.S. Appl. No. 11/781,152 mailed Nov. 13, 2008.
Rudolphus, A., et al., “Intratracheally-Instilled antileukoprotease and α1-Proteinase Inhibitor: Effect on Human Neutrophil Elastase-Induced Experimental E
Barr Philip J.
Gibson Helen L.
Pemberton Philip A.
Arnold and Porter LLP
Arriva Pharmaceuticals, Inc.
Bernhardt Jeffrey P.
Kam Chih-Min
LandOfFree
Treatment of chronic obstructive pulmonary disease by low... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chronic obstructive pulmonary disease by low..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chronic obstructive pulmonary disease by low... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779915